• Enanta Pharmaceuticals dosed the first patient in RESOLVE, a Phase 2b/3 trial of zelicapavir for adults at high risk from RSV.
• Phase 2b results are expected in 2027, with at least 200 patients; Phase 3 is expected to enroll approximately 660.
• Eligible outpatients must have RSV symptoms for no more than three days, with advanced age or specified heart or lung conditions.
• The primary endpoint is complete resolution of all 13 RSV symptoms; hospitalization rate is a key secondary endpoint.
• A previous Phase 2 trial showed a one-week reduction in time to complete symptom resolution among similarly high-risk patients, with fewer hospitalizations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026346472) on October 26, 2026, and is solely responsible for the information contained therein.